Clinical trial
Tesmilifene in Combination With Docetaxel in the Treatment of Metastatic Breast…
NCT00364195 · YM BioSciences, Industry · Completed
Key facts
| NCT number | NCT00364195 |
|---|---|
| Title | Tesmilifene in Combination With Docetaxel in the Treatment of Metastatic Breast Cancer |
| Official title | A Pharmacokinetic Interaction and Safety and Efficacy Phase II, Open Label Study With a Safety Lead-in Evaluating Docetaxel Plus Tesmilifene (YMB1002) in Patients With Metastatic Breast Cancer Suitable for Treatment With Docetaxel |
| Lead sponsor | YM BioSciences, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Tesmilifene (YMB1002) |
| Enrollment | 33 |
| Start date | Jun 1, 2006 |
| First posted | Aug 15, 2006 |
| Last update posted | Jan 9, 2009 |
| Countries | Serbia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: